Background-In the day to day care of obstructive airways diseases (asthma and chronic obstructive pulmonary disease) inportant decisions such as disease classification and choice of therapy are based on assessment of the bronchodilator response. However, surprisingly little is known of the long term course of the bronchodilator response in patients with obstructive airways disease. Methods-Data from a multicentre trial were used in which 274 patients aged 18-60 years with airways obstruction were selected with PC20 < 8 mglml and FEVy < 95% CI of predicted. FEV, was measured before and 20 minutes after 1000 ug terbutaline and 40 minutes after an additonal 80 pg ipratropium bromide. Data were analysed from 185 patients who were followed up for 21 months (five measurements). Four different expressions of bronchodilator response (BDR) were examined for change under long term therapy, long term variability, and prognostic value in predicting response to inhaled corticosteroids. Results-There was a significant reduction in BDR of 117 ml after three months of treatment with a /i agonist plus a corticosteroid (BA + CS), but not after bronchodilators only. Significant reductions with BA + CS were also found in BDR as a percentage of initial FEV,, and in BDR as a percentage of predicted FEV,. Bronchodilator tests were quite variable (SD 186 ml or 11% of initial value) and less than half of the patients could consistently be classified as "irreversible" with recommended cutoff levels. The bronchodilator response at the start of the study proved to be a poor predictor of improvement in FEVy under BA + CS treatment (correct prediction 60%). Conclusions-Bronchodilator responses decrease substantially with inhaled corticosteroid therapy, and within subject variability is considerable both in asthma and chronic obstructive pulmonary disease. Dichotomous decisions on whether
Data were analysed from 185 patients who were followed up for 21 months (five measurements). Four different expressions of bronchodilator response (BDR) were examined for change under long term therapy, long term variability, and prognostic value in predicting response to inhaled corticosteroids. Results-There was a significant reduction in BDR of 117 ml after three months of treatment with a /i agonist plus a corticosteroid (BA + CS), but not after bronchodilators only. Significant reductions with BA + CS were also found in BDR as a percentage of initial FEV,, and in BDR as a percentage of predicted FEV,. Bronchodilator tests were quite variable (SD 186 ml or 11% of initial value) and less than half of the patients could consistently be classified as "irreversible" with recommended cutoff levels. The bronchodilator response at the start of the study proved to be a poor predictor of improvement in FEVy under BA + CS treatment (correct prediction 60%). Conclusions-Bronchodilator responses decrease substantially with inhaled corticosteroid therapy, and within subject variability is considerable both in asthma and chronic obstructive pulmonary disease. Dichotomous decisions on whether patients are "irreversible" according to any single bronchodilator measurement should therefore be made with great caution. The bronchodilator response cannot be used accurately as a predictor of response to inhaled corticosteroids in obstructive airways disease. (Thorax 1993; 48:722-729) Assessment of bronchodilator response (BDR) in patients with obstructive airways disease is a routine procedure both in clinical practice and research. The results of the test are used to separate patients with asthma both from normal subjects and from those with chronic obstructive pulmonary disease (COPD) and to make therapeutic decisions.' There are, however, numerous problems associated with bronchodilator testing.
The interpretation of any test requires knowledge about its variability. Although data are available for patients with COPD,' no such data exist on the variability of bronchodilator testing in patients with asthma. In addition there is no consensus on how to express the BDR. The most commonly used expression-the response as a percentage of the initial value-has the disadvantage that the response is highly dependent on the initial (baseline) value. [3] [4] [5] There is also no consensus on what constitutes a "significant" BDR.2-7 The American Thoracic Society has recently issued new guidelines recommending that a "significant" BDR should be both larger than a 12% increase over baseline and larger than 200 ml.' To our knowledge, no published data exist to support this recommendation. Finally, the use of the BDR for therapeutic decisions has been studied in patients with COPD where a larger BDR predicted, to some extent, a larger improvement with oral corticosteroids,9-1' but whether a higher BDR predicts a more favourable reaction to inhaled corticosteroid therapy in obstructive airways disease is unknown.
We have studied the BDR prospectively in a large group of patients with obstructive airways disease (asthma and COPD) and a broad range of clinical presentations and lung function. They were randomly allocated to one of three different treatment regimens (inhalation of a single bronchodilator, two bronchodilators, or a bronchodilator and a corticosteroid), and followed up for 2 5 Vanrability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease 
ation in results is due to differences between subjects and a value of 0 denotes that all variation is due to within subject variation alone (biological + measurement error).18 Linear regression analysis was employed to study the relationship between variables over time for the group as a whole, and within subject Spearman rank correlation coefficients (p) for within subject relations over time. The rate of change of FEVy and BDR over 21 months and the associated standard deviations were calculated for each patient by least squares linear regression. Analyses were performed using the SPSS/PC + package. '9 Results 9 15 
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The results of the intervention study in terms Months of differences in withdrawal rate, FEV1, and PC20 between patients treated with and without inhaled corticosteroids have been pubiethods used included t lished elsewhere."3 Briefly, 12 (19) and +13 (19) in the BA + PL and BA + AC groups respectively, fig 2A) . fig 2D) . In the BA + AC and BA + PL groups there were no significant changes from baseline over time with any of the BDR expressions, nor were the slopes of the changes over time significantly different from zero.
The decrease in BDR in three months in the BA + CS group was correlated to the increase in prebronchodilator FEV,%pred in three months, more strongly so when expressed as BDR%init (r = -0-65) than as BDR[ml] (-0 52), BDR%pred (-0-51), or BDR-SR (-0-51), all p < 0-001.
To determine to what degree the decrease in BDR in the BA + CS treated group was caused by the FEV, reaching normal levels the data were recalculated for a subgroup of 49 patients whose FEV, value after terbutaline remained more than 1-64 RSD below the predicted value after three months of treatment-that is, whose post-terbutaline FEV, remained abnormal. The decrease in BDR [ml] in the first three months diminished to -61 (39) ml (p > 01), the decrease in BDR%init to -5 0% (2d1%) (p < 0-05), BDR%pred to -2-0% (1-1%) (p > 0-05), and BDR-SRto -0-16 (0 1) (p > 0 05).
Additional administration of 80 pg of ipratropium bromide immediately after terbutaline (1000 jug) gave a mean additional dilatation of 197 (30) ml before and 200 (24) ..... ml after three months of treatment with inhaled corticosteroids (fig 3) . In the subgroup of 49 patients whose post-terbutaline
FEVy value remained more than 1 64 RSD below predicted as described above, the additional increase with ipratropium bromide after terbutaline amounted to 227 ml (more than 100 ml in 39 of 49 patients). Theoretically airway calibre can be decreased by at least five mechanisms25: decreased preload, increased smooth muscle tone, increased smooth muscle strength (hypertrophy, hyperplasia), airway wall thickening due to hypertrophy and hyperplasia of muscles and glands, oedema, influx of inflammatory cells, and secretions within the airway lumen. In this study prebronchodilator FEV, after three months of treatment with corticosteroids rose to approximately the post-terbutaline value at the start of the study. This could indicate that the improvement in airways obstruction with inhaled corticosteroids is due to a decrease in bronchomotor tone only. However, after three months the mean BDR to terbutaline was still 300 ml, compared with 417 ml at the initial visit. This suggests that inhaled corticosteroids also cause an alteration in airway geometry apart from the change in bronchomotor tone, which is well in line with the proposed antiinflammatory effects of inhaled corticosteroids (reduction of number of inflammatory cells and decreases in release of cytokines and mediators thereby reducing airway wall thickness, airway secretions and muscle tone).26 Although in our study FEV1 and BDR showed no further change after three months of corticosteroid treatment and hence the maximum improvement in smooth muscle tone and airway geometry had been achieved, airway hyperresponsiveness to histamine nevertheless continued to improve until at least one year of treatment in the same patient population."3 It is possible that more sensitive measurements than FEV1 would still detect improvements in airway resistance in parallel with further improvements in the extent of inflammation as measured by PC20. Other explanations for continuing improvement in PC20 without concomitant change in airway calibre seem more appealing, however, such as improvements in epithelial healing and decreases in permeability which would not by itself affect airway geometry.
As indicated above, only part of the improvement in the level of airways obstruction is caused by a decrease in bronchomotor tone. This by itself already suggests that a BDR measured before treatment with inhaled corticosteroids will not accurately predict the change in FEV, caused by their use. Although significant regression coefficients were found between baseline BDR and long term improvement in FEV1, the maximum correlation coefficient was 0-52 signifying 27% explained variance. The correct prediction of a favourable long term response was calculated using the baseline BDR as the test: only approximately 60% of patients would have been correctly given or withheld inhaled corticosteroids. This correct prediction of an "inhaled corticosteroids responder" by a pretreatment BDR was slightly better in COPD than in asthma, but because of the small numbers it is uncertain whether any firm conclusions should be attached to the difference-that is, whether a single bronchodilator test is more useful as a prognostic test for inhaled corticosteroids in COPD than it is in asthma.
Surprisingly few data have hitherto been published on long term variability of BDR in asthma and COPD. Considerable within subject variability of BDR was found in this study, which was performed under rigorously controlled trial conditions, all patients being on maintenance medication and without measurements during or shortly after exacerbations (table 2) . The standard deviations of BDR found are comparable to those reported by Anthonisen et al in patients with COPD participating in the IPPB trial.2 Even though we found significant differences (but with a large overlap) in BDR between the different diagnosis groups,4 within subject standard deviations were quite comparable for patients with a symptom based diagnosis of asthma or COPD (table 2) .
The American Thoracic Society has recently recommended a new criterion for the definition of a "significant" bronchodilator response, again from one test (a change in FEV, larger than 12%init and larger than 200 ml). Table 3 shows that in this large group of patients with a broad range of clinical characteristics, variability in the result of a single test is not reduced by the new ATS criterion.
Although the decrease in BDR with inhaled corticosteroids is probably not surprising, to our knowledge it has not been documented to date. In many guidelines for the management of obstructive airways disease it is recommended that healthy subjects should be distinguished from those with obstructive airways disease, and reversible airways obstruction should be distinguished from irreversible airways obstruction on the basis of a (single) bronchodilator test.' 27 The results of our study suggest that this is hazardous, both because of a high within subject variability and because of a decrease in BDR during treatment with inhaled corticosteroids. We feel that one single bronchodilator test is clearly insufficient to make a diagnosis of "(ir)reversible" airways obstruction, and hence to classify a patient as having asthma or COPD on the basis of the test.
From cross sectional data several authors have stressed the dependence on baseline FEV, of the BDR when expressed as a percentage of the initial value.2 4 From our longitudinal data we document further manifestations of this baseline dependency: changes in BDR%init were more dependent on improvements in prebronchodilator FEV, with corticosteroid treatment than the other expressions employed. Similarly, in the nonsteroid treated groups the within subject variability of BDR was most closely linked to variability in prebronchodilator FEV, when expressed as %init.5 From the data presented in this report no clearcut argument can be given in favour of any one of the expressions of BDR. Expressing the BDR relative to the predicted FEVI, however, makes some correction for gender, height, and age which makes comparison between patients and between studies easier. 4 Expressing the FEVy, and hence the BDR, relative to the standardised residual offers theoretical advantages'415 but no advantages in the sense of decreased baseline dependency or decreased variability in this study.
The study population was selected on the basis of symptomatic respiratory disease, age, and objective functional criteria of airways obstruction (FEVI, FEV,IVC) and airway responsiveness (PC2o histamine). Selection bias of a certain level of reversibility to a R agonist was therefore not introduced. Because considerable dropout occurred in both treatment arms without inhaled corticosteroids, however, the current selection from our original population introduced bias to some extent. Withdrawals had slightly lower baseline FEV,%pred and lower PC20 than non-withdrawals, but no significant differences were found in BDR. Since more than 70% of withdrawals resulted from increases in respiratory symptoms it seems likely that, if anything, variability of the BDR in the currently selected group is a conservative estimate of the true variability in our original population.
In conclusion, BDR decreases substantially with inhaled corticosteroid therapy. This improvement is related to the improvement in FEV, which is caused by both altered airway geometry and a decrease in bronchomotor tone as measured by a decreased BDR. Moreover, measurements of BDR are very variable over 21 months. These results suggest that a single BDR should not be used as the basis for therapeutic decisions nor as a selection criterion for clinical trials. These problems are greatest with a BDR expressed as a percentage of the initial value because of its dependency on baseline FEV,. Finally, because of the imperfect relation between the bronchodilator test before inhaled corticosteroids and the future response to them, we think that therapeutic decisions on whether or not to prescribe corticosteroids should not be made on the basis of bronchodilator tests, but probably on combined information from symptoms, FEV1, PC20, peak flow, atopy, and BDR.
